EpCAM-targeted therapy for human hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Cancer Therapeutics
• Molecular Oncology

Background:

• Hepatocellular carcinoma (HCC) is a highly lethal malignancy requiring novel therapeutic strategies.
• EpCAM, a hepatic stem/progenitor marker, has been identified as a prognostic predictor in HCC patients.
• This study evaluates VB4-845, an immunotoxin targeting EpCAM, for HCC treatment.

Purpose of the Study:

• To assess the in vitro and in vivo efficacy of VB4-845 in hepatocellular carcinoma (HCC).
• To investigate the effects of VB4-845 on HCC cell cytotoxicity, sphere-forming ability, and stem/progenitor marker expression.
• To evaluate the therapeutic potential of VB4-845, alone and in combination with 5-FU, in preclinical HCC models.

Main Methods:

• In vitro analysis of VB4-845 on human HCC cells, including cytotoxicity and sphere formation assays.
• Assessment of stem/progenitor marker expression (EpCAM, CD133, CD13) in HCC cells.
• In vivo evaluation using subcutaneous and orthotopic liver xenograft models in mice.

Main Results:

• VB4-845 demonstrated potent cytotoxicity against EpCAM-expressing HCC cells, significantly enhanced by 5-FU.
• VB4-845 suppressed sphere-formation and reduced CD133 and CD13 expression, unlike 5-FU alone.
• Combination therapy of VB4-845 and 5-FU led to significant tumor regression in both subcutaneous and orthotopic xenograft models.

Conclusions:

• EpCAM-targeted therapy with VB4-845 shows promise as a novel treatment for HCC.
• The combination of VB4-845 and 5-FU exhibits significant preclinical efficacy against HCC.
• Targeting EpCAM may offer a new therapeutic avenue for HCC patients with poor prognoses.